BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/4/2025 7:41:48 AM | Browse: 333 | Download: 1052
Publication Name World Journal of Clinical Cases
Manuscript ID 101742
Country China
ISSN 2307-8960 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Medicine, Research & Experimental
Manuscript Type Clinical Trials Study
Article Title Prediction of the efficacy of first transarterial chemoembolization for advanced hepatocellular carcinoma via a clinical-radiomics model
Manuscript Source Unsolicited Manuscript
All Author List Kai-Fei Zhao, Chao-Bang Xie and Yang Wu
ORCID
Author(s) ORCID Number
Kai-Fei Zhao http://orcid.org/0000-0002-8274-2600
Chao-Bang Xie http://orcid.org/0000-0001-6976-4357
Yang Wu http://orcid.org/0000-0003-1976-7968
Funding Agency and Grant Number
Corresponding Author Yang Wu, Department of Intervention, The second Affiliated Hospital of Zunyi Medical University, Intersection of Xinlong Avenue and Xinpu Avenue in Xinpu New District, Zunyi City, Zunyi 563000, Guizhou Province, China. 1096945853@qq.com
Key Words Hepatocellular carcinoma; Transarterial chemoembolization; Radiomics; Computed tomography; Prognosis; Treatment response
Core Tip Hepatocellular carcinoma (HCC) is often diagnosed at advanced stages, where transarterial chemoembolization (TACE) serves as a key therapy. However, nearly 50% of patients show poor TACE response due to tumor heterogeneity. This study integrates preoperative computed tomography radiomics and clinical factors to build a predictive model for TACE efficacy. Radiomics noninvasively extracts quantitative imaging features reflecting tumor pathophysiology, enabling precise assessment of treatment response. The combined model stratifies patients by predicted risk, guiding timely transition to alternative therapies (e.g., targeted drugs or immunotherapy) for non-responders. This approach enhances personalized HCC management, optimizes resource allocation, and improves survival outcomes through data-driven clinical decision-making.
Publish Date 2025-06-04 07:41
Citation

Zhao KF, Xie CB, Wu Y. Prediction of the efficacy of first transarterial chemoembolization for advanced hepatocellular carcinoma via a clinical-radiomics model. World J Clin Cases 2025; 12(23): 101742

URL https://www.wjgnet.com/2307-8960/full/v13/i23/101742.htm
DOI https://dx.doi.org/10.12998/wjcc.v13.i23.101742
Full Article (PDF) WJCC-13-101742-with-cover.pdf